What Vascepa Does to Cholesterol and Triglycerides
Vascepa (icosapent ethyl) is an EPA-only omega-3 prescription used with statins in patients with high triglycerides (≥150 mg/dL) and other cardiovascular risks. It lowers triglycerides by 18-45% at 4g daily doses but does not raise LDL cholesterol (the "bad" cholesterol). In statin users, it often reduces non-HDL cholesterol and ApoB without worsening LDL-C.[1][2]
How Vascepa Differs from Statins Alone
Statins primarily cut LDL-C by 20-60% depending on dose and type (e.g., atorvastatin, rosuvastatin), while mildly lowering triglycerides (10-30%) and raising HDL slightly. Adding Vascepa to statins targets persistent high triglycerides that statins don't fully address, improving overall lipid control without the LDL-C spike seen with some other omega-3s like Lovaza.[1][3]
Evidence from Key Trials on Statin + Vascepa Combo
The REDUCE-IT trial tested Vascepa 4g/day plus statins in 8,179 high-risk patients. Results showed:
- Triglycerides dropped 19.7%.
- LDL-C stayed stable (no increase).
- Non-HDL-C fell 13.9%, ApoB 11.1%.
This combo cut major cardiovascular events by 25% vs. statins alone.[2][4]
| Lipid Parameter | Statins Alone (Typical) | + Vascepa (REDUCE-IT) |
|-----------------|--------------------------|-----------------------|
| Triglycerides | ↓10-30% | ↓19.7% |
| LDL-C | ↓20-60% | Stable (no ↑) |
| Non-HDL-C | ↓15-50% | ↓13.9% |
| HDL-C | ↑5-15% | Stable |
Does Vascepa Ever Raise LDL Cholesterol with Statins?
No consistent LDL-C increase occurs; REDUCE-IT confirmed stability even in patients with baseline LDL-C 40-100 mg/dL on statins. This avoids risks from mixed EPA/DHA omega-3s, which can raise LDL-C 10-20% in some cases.[1][3]
Who Gets Vascepa with Statins and When?
Prescribed for adults on max-tolerated statins with triglycerides 150+ mg/dL, plus atherosclerosis or diabetes with risks. Not for standalone use or primary LDL-C lowering—statins handle that.[1]
Potential Downsides on Lipids or Overall
Common side effects include muscle pain (with statins), bleeding risk, or atrial fibrillation (3% higher in trials). No major lipid disruptions, but monitor triglycerides quarterly initially.[1][2]
[1]: Vascepa Prescribing Information (FDA)
[2]: REDUCE-IT Trial (NEJM, 2019)
[3]: DrugPatentWatch.com - Vascepa Patents & Lipids
[4]: Amarin REDUCE-IT Summary